Results 141 to 150 of about 9,404 (185)
Some of the next articles are maybe not open access.
0579 Long-Term Safety of Once-Nightly Oxybate for Narcolepsy: RESTORE Study Interim Analysis of Data
Sleep, 2023Abstract Introduction The pivotal phase 3 REST-ON trial (NCT02720744) evaluated the efficacy and safety of once-nightly sodium oxybate (ON-SXB; FT218), an investigational extended-release formulation for treatment of adults with narcolepsy. In REST-ON, ON-SXB met its 3 coprimary endpoints: improvement
Thomas Stern +7 more
exaly +2 more sources
The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study [PDF]
Journal of Acquired Immune Deficiency Syndromes (1999), 2010 peer reviewed[en] OBJECTIVE: To determine the impact of once-nightly versus twice-daily dosing and beliefs about highly active antiretroviral therapy (HAART) on adherence to efavirenz-based HAART in antiretroviral-naive patients. METHODS: A multicenter,
Vanessa Cooper +2 more
exaly +2 more sources
0589 Dose Titration of Once-Nightly Sodium Oxybate: Analysis of Interim Data From RESTORE
SLEEP, 2023Abstract Introduction FT218 (LUMRYZ™) is an investigational once-nightly sodium oxybate (ON-SXB) for treatment of adults with narcolepsy type 1 (NT1) or type 2 (NT2). The efficacy and safety of ON-SXB at doses 6, 7.5, and 9 g in patients with NT1/NT2 were confirmed in the phase 3 REST-ON clinical ...
Asim Roy +5 more
openaire +1 more source
SLEEP, 2023
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release treatment, was evaluated for the treatment of narcolepsy in adults in the phase 3 REST-ON clinical trial (NCT02720744).
Thomas Roth +6 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; FT218), an investigational, extended-release treatment, was evaluated for the treatment of narcolepsy in adults in the phase 3 REST-ON clinical trial (NCT02720744).
Thomas Roth +6 more
openaire +1 more source
0638 Stability of Once-Nightly Sodium Oxybate in Alternative Liquid Reconstitution Vehicles
SLEEPAbstract Introduction LUMRYZ™ is a once-nightly formulation of sodium oxybate (ON-SXB) containing both immediate and pH-dependent controlled-release granules designed to be reconstituted in water and administered orally.
Maggie Lavender +6 more
openaire +1 more source
SLEEP
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +1 more source
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
Clinical Neuropharmacology, 2018
Abstract Fluoxetine is a selective serotonin reuptake inhibitor that is commonly used in children and adolescents. Several reports exist regarding the relationship of fluoxetine use and sleep bruxism. We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism,
Betül, Akbaş, Ayhan, Bilgiç
openaire +2 more sources
Abstract Fluoxetine is a selective serotonin reuptake inhibitor that is commonly used in children and adolescents. Several reports exist regarding the relationship of fluoxetine use and sleep bruxism. We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism,
Betül, Akbaş, Ayhan, Bilgiç
openaire +2 more sources
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Data From RESTORE
Sleep Medicine, 2022T. Stern +8 more
openaire +1 more source
DOSE TITRATION AND TOLERABILITY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM DATA FROM RESTORE
Chest, 2022ASIM ROY +5 more
openaire +1 more source